Skip to main content
Equibles
INSM logo

INSM · INSMED Inc · Metrics

Track INSM — free

Use INSM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research INSM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$121.16 +3.09 (+2.62%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
Russell 1000 member Rebalance outlook locked
Market Cap
$26.58B
Shares
219.38M
Volume · Nov 13 1.54M Avg daily vol (3M) 2.77M

INSM metrics

92 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$121.16
Market cap
$26.58B

Price action

23 metrics
Price change (1W)
+5.9%
Price change (30D)
+22.1%
Price change (3M)
-2.1%
Price change (6M)
+11.0%
Price change (YTD)
-30.4%
Price change (1Y)
-36.6%
Trailing year
Price change (5Y)
+280.3%
52-week high
$211.41
52-week low
$91.88
Change from 52-week high
-42.7%
Change from 52-week low
+31.9%
Annualized volatility
63.1%
Annualized volatility (3M)
49.5%
Implied volatility (30D)
45.0%
IV rank (1Y)
18.1
IV percentile (1Y)
20.5
Beta
0.6
RSI (14D)
65.0
Price vs SMA 50
+9.3%
Price vs SMA 200
-1.6%
Avg volume (3M)
2.77M
Relative volume
0.6
Average dollar volume
$308.12M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
219.38M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
17.1×
reciprocal yield 5.8%
EV / EBITDA
—
EV / EBIT
—
P / sales
17.5×
reciprocal yield 5.7%
P / book
36.6
reciprocal yield 2.7%
FCF yield
-2.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-2.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
36.7×
reciprocal yield 2.7%
EV / revenue historical average (5Y)
27.2×
reciprocal yield 3.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-29

Profitability

9 metrics
Gross margin
84.4%
Operating margin
-37.1%
Trailing 12 months
Net margin
-39.9%
Gross profit (TTM)
$1.28B
Operating profit (TTM)
−$563.99M
Net income (TTM)
−$605.61M
Trailing 12 months
Diluted EPS (TTM)
$-2.83
FCF margin
-41.3%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$7.01
Gross profit per diluted share (TTM)
$5.92
Operating profit per diluted share (TTM)
$-2.62
EBITDA per diluted share (TTM)
$-2.51
Net income per diluted share (TTM)
$-2.82
Operating cash flow per diluted share (TTM)
$-2.77
Free cash flow per diluted share (TTM)
$-2.92
Capital expenditures per diluted share (TTM)
$0.15
R&D per diluted share (TTM)
$4.37
Stock compensation per diluted share (TTM)
$0.77
Book value per share
$3.45

Growth

11 metrics
Revenue growth YoY
+268.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.52B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.3%
Year over year · more shares
Revenue CAGR (3Y)
+35.2%
Revenue CAGR (5Y)
+29.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-83.4%
Return on assets
-27.2%
Debt / equity
0.8
Current ratio
2.9
EBITDA (TTM)
−$539.75M
Free cash flow (TTM)
−$627.58M
Quick ratio
2.6
Interest coverage
-6.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$591.53M
Latest balance sheet
Cash & equivalents
$396.56M
Total assets
$2.23B
Total debt
$555.09M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$595.62M
Capital expenditures (TTM)
$31.95M
R&D (TTM)
$944.39M
SG&A (TTM)
$960.24M
Stock compensation (TTM)
$167.27M
R&D / revenue
62.1%
Stock compensation / revenue
11.0%

Ownership (13F)

9 metrics
13F filers
670
13F filer change QoQ
-10
Institutional ownership
105.8%
Conviction holders (share of 13F filers)
2.4%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+0.9%
Holder tenure
15.0
Price vs estimated holder cost
+4.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
15.9%

Short interest

3 metrics
Short interest
6.4%
Latest settlement · 3.6 days to cover
Days to cover
3.6d
Short-squeeze score
67 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$3.74M
Insider-sentiment score
25 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1104506 CUSIP 457669307 13F (30d) 550 filings 499 filers Visit website Investor relations